|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The commonplace expression of the ROS1 oncogene in meningiomas suggests a role for this oncogene in the etiology of these tumors.
|
7553586 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis yielded 20 novel genes differentially expressed in both lung adenomas and ACs versus normal lungs, including the tumor suppressor APC2 and the oncogene Ros 1.
|
14647414 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We identified and characterized the c-ROS gene promoter region and report that the ectopic expression of c-ROS in tumors is tied to hypomethylation of a CpG island in the c-ROS promoter.
|
19276365 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consequently endogenous ROS generation in DU-145 tumor spheroids was increased in the presence of either IA or 2-DDG, which was abolished upon coincubation with ebselen.
|
19950199 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Some of the ALK and ROS1 rearranged tumors may also harbor coexisting EGFR mutations.
|
22661537 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ROS1 inhibition may be an effective treatment strategy for the subset of patients with NSCLC whose tumors express ROS1 fusion genes.
|
22919003 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Crizotinib has recently been shown to be an effective ROS1 inhibitor in ROS1-rearranged NSCLC, with potential future clinical applications in ROS1-rearranged tumors.
|
22989574 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Twenty-three tumor samples were ROS1 IHC-positive.
|
23400546 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting ROS1 fusion proteins with the small-molecule inhibitor crizotinib is showing promise as an effective therapy in patients with NSCLC whose tumors are positive for these genetic abnormalities.
|
23719267 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ROS1 protein expression in tumor cells is 100% sensitive and 92% specific for ROS1 rearrangements by FISH.
|
23887156 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, eIF2αP-deficient human tumor cells are highly susceptible to extrinsic ROS generated by the pro-oxidant drug doxorubicin by undergoing premature senescence.
|
24334569 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To accomplish this, we analyzed tumor samples from a patient who initially responded to the ROS1 inhibitor crizotinib but eventually developed acquired resistance.
|
24349229 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In recurred NSCLC, ROS1 expression was significantly higher in recurring tumors (38%) than primary tumors (19%).
|
22915320 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We performed a biopsy of a resistant tumor and identified an acquired mutation leading to a glycine-to-arginine substitution at codon 2032 in the ROS1 kinase domain.
|
23724914 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fluorescence in situ hybridization using ROS1 break-apart probes revealed positive rearrangement signals in 23% to 93% of the tumor cells in ROS1 fusion-positive cancers, which were readily distinguished using a 15% cutoff value from 50 ROS1 fusion-negative tumors tested, which showed 0% to 6% rearrangement signals.
|
23426121 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, it was reported that ROS1 expression was observed in diverse cancer tissue or cell lines and ROS1 is associated with the development of several tumors.
|
23549810 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On retesting the patient's tumor sample was found to harbor a ROS1-translocation.
|
23558310 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The recent discovery and characterization of an oncogenic ROS1 gene fusion in a subset of lung cancers has raised significant clinical interest because small molecule inhibitors may be effective to these tumors.
|
24186139 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ROS1 rearrangements have been detected in a variety of tumors and are considered as suitable targets of anticancer therapies.
|
25231053 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumors with ROS1 fusions had significantly larger diameter than ROS1 fusion-negative tumors (P = 0.007), whereas all the 15 tumors harboring RET fusions were ≤ 3 cm in diameter (P = 0.001).
|
24629636 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Then, we confirmed antitumorigenic effects of TA in a nude mouse orthotopic ATC model, and this result accompanied the augmentation of NAG-1 expression and ROS generation in tumor tissue.
|
24216474 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We identified seven ROS1 and 14 RET fusion-positive tumors and confirmed the fusion status by RT-PCR and FISH.
|
24418728 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The concept of using information from a patient's tumor to make therapeutic and treatment decisions has revolutionized the landscape for cancer care and research in general.Management of non-small-cell lung cancer, in particular, has seen several of these advances, with the understanding of activating mutations in EGFR, fusion genes involving ALK, rearrangements in ROS-1, and ongoing research in targeted therapies for K-RAS and MET.
|
24292963 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Considering a positivity threshold of 2+ stained cells, the sensitivity of the ROS1 D4D6 antibody compared to FISH was 100% and the specificity 96.9%, as two HER2-mutated tumors were positive with D4D6 antibody, without any translocation in FISH.
|
24380695 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Acinar (including cribriform) and solid patterns were the two most common histologic subtypes in the ROS1 fusion tumors (7 of 12, 58.3%) and were predominantly seen in CD74-ROS1 fusion tumors (66.7%).
|
25157770 |
2014 |